X4 Pharmaceuticals/$XFOR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About X4 Pharmaceuticals
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Ticker
$XFOR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
143
ISIN
US98420X2027
Website
XFOR Metrics
BasicAdvanced
$23M
1.87
$2.16
0.58
-
Price and volume
Market cap
$23M
Beta
0.58
52-week high
$6.63
52-week low
$2.67
Financial strength
Current ratio
3.697
Quick ratio
3.405
Long term debt to equity
334.458
Total debt to equity
340.137
Interest coverage (TTM)
-12.49%
Management effectiveness
Return on assets (TTM)
-58.61%
Return on equity (TTM)
121.75%
Valuation
Price to earnings (TTM)
1.867
Price to revenue (TTM)
0.869
Price to book
1.02
Price to tangible book (TTM)
-5.54
Price to free cash flow (TTM)
-0.227
Growth
Earnings per share change (TTM)
-110.70%
3-year earnings per share growth (CAGR)
-72.44%
XFOR News
AllArticlesVideos
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 days ago
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
GlobeNewsWire·3 weeks ago
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for X4 Pharmaceuticals stock?
X4 Pharmaceuticals (XFOR) has a market cap of $23M as of June 06, 2025.
What is the P/E ratio for X4 Pharmaceuticals stock?
The price to earnings (P/E) ratio for X4 Pharmaceuticals (XFOR) stock is 1.87 as of June 06, 2025.
Does X4 Pharmaceuticals stock pay dividends?
No, X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next X4 Pharmaceuticals dividend payment date?
X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders.
What is the beta indicator for X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.